Main Article Content


The sustain release study and comparison study between new formulated and existing drug in marketed drug by using the animal modal Sorafenib (SOR). The anti-cancer drug was used for this study and the study was carried out using UPLC. The chitosan biopolymer is used as a drug carrier. The nano-polymeric pharmaceutical excipient such as chitosan nanoparticles (CS-NPs) was synthesized for formulating the anticancer drug Sorafenib (SOR). The formulation was done through the simple ionic cross-linking method. The prepared formulation was characterized by   SEM, UV VISs and SEM. The SEM study reveals that the Sorafenib loaded chitosan nanoparticles (SNB-CS-NPs) were in the size range of less than 200 nm. Encapsulation of Sorafenib and validation for the formulation was done using UPLC. In vivo drug release was performed for SOR-CS-NPs and the marketed drug in mice. This study implies the drug delivery system for Sorafenib for the effective sustained delivery in animals and its compared to the existing marketed drug.


sorafenib chitosan nanoparticles validation ionic crosslinking

Article Details

How to Cite
Joseph, J. J., Sangeetha, D., Gomathi, T., & Balamurugan, T. (2021). Formulation and Evaluation of the Anticancer Drug: Sorafenib. Trends in Biomaterials & Artificial Organs, 35(4), 336-338. Retrieved from

Most read articles by the same author(s)